Why Grand Pharmaceutical Group (SEHK:512) Is Back In The Spotlight

Grand Pharmaceutical Group earnings trigger fresh look at the stock

Grand Pharmaceutical Group (SEHK:512) has drawn attention after reporting half year 2026 earnings, with sales of HK$6,388.91 million and net income of HK$1,061.54 million, alongside lower basic earnings per share.

At a latest share price of HK$4.91, Grand Pharmaceutical Group has seen its 1-day share price return edge up 0.61%, although the 7-day and 30-day share price returns are down 6.30% and 4.01% respectively. Year to date, the share price return is down 37.05% and the 1-year total shareholder return is down 43.43%, while the 3-year total shareholder return of 40.45% shows that longer term holders have had a very different experience to more recent investors.

Compare Grand Pharmaceutical Group's mixed share price performance with hand picked companies on our 257 high quality undervalued stocks that also pair earnings power with balance sheet strength.

Grand Pharmaceutical Group now trades at a steep discount to both analyst targets and one estimate of intrinsic value, yet the latest earnings have clearly cooled sentiment. Is the market being too harsh, or simply cautious for a reason?

Price to earnings of 15.5x for Grand Pharmaceutical Group: Is it justified?

On valuation metrics alone, Grand Pharmaceutical Group trades on a P/E of 15.5x at a share price of HK$4.91, which suggests the stock is priced below some estimates of fair value yet not obviously cheap relative to all benchmarks.

The P/E multiple compares the current share price to earnings per share, so it reflects what investors are willing to pay for each dollar of current earnings. For a pharmaceutical company like Grand Pharmaceutical Group, this often embeds expectations about the durability of existing products and the potential of its research and development pipeline across respiratory, ophthalmology, cerebro-cardiovascular emergency and biotechnology products.

Relative to peers selected for comparison, Grand Pharmaceutical Group is described as good value at 15.5x earnings when set against a peer average P/E of 34.4x. When compared to an estimated fair P/E of 19.2x from the SWS model, the current multiple also screens lower, which points to room for the valuation to move closer to that fair ratio if earnings forecasts and cash flows materialise as expected. However, against the Hong Kong pharmaceuticals industry average P/E of 14.4x, the stock trades at a premium, so the current price still assumes stronger prospects than the broader local sector.

To understand how that fair ratio is calculated and what it implies for Grand Pharmaceutical Group, review the Explore the SWS fair ratio for Grand Pharmaceutical Group

Result: Price-to-earnings of 15.5x (UNDERVALUED)

However, investors still need to weigh the sharp 1-year and 5-year total shareholder return declines against execution risks in Grand Pharmaceutical Group's diverse product and geographic mix.

Find out about the key risks to this Grand Pharmaceutical Group narrative.

Another view on Grand Pharmaceutical Group's valuation

The earlier P/E check suggested Grand Pharmaceutical Group looks inexpensive relative to some peers. A different lens tells a stronger story. Our DCF model estimates the value of future cash flows at about HK$18.95 per share, while the current price is HK$4.91. That points to a wide undervaluation gap that raises a simple question: Is the market pricing in risks that are not yet clear, or is this a mispricing that could close over time?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Grand Pharmaceutical Group for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 257 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With sentiment on Grand Pharmaceutical Group looking finely balanced, it may be useful to take a closer look and review the full picture yourself. To weigh both the potential rewards and the key risks around this stock, start with the 2 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Grand Pharmaceutical Group?

If Grand Pharmaceutical Group has caught your attention, do not stop there. Cast a wider net now so you do not miss other compelling opportunities on Simply Wall St.

• Target reliable cash generators by reviewing companies with strong cash flows and healthy balance sheets in the 257 high quality undervalued stocks.
• Strengthen the defensive side of your portfolio by focusing on companies with robust finances using the list of solid balance sheet and fundamentals (438 results).
• Get ahead of the crowd by scanning for lesser known opportunities with solid fundamentals in the 617 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com